Nicotine is commonly co-used with other psychostimulants. These high rates of co-use have prompted much research on the interaction of nicotine and various psychostimulant drugs. These studies range from examination of illicitly used psychostimulants such as cocaine and methamphetamine to prescription psychostimulants used in the treatment of attention deficit hyperactivity disorder such as methylphenidate (Ritalin™) and d-amphetamine (active ingredient of Adderall™). However, previous reviews largely focus on the interaction between nicotine and illicitly used psychostimulants with sparse mention of prescription psychostimulants. The currently available epidemiological and laboratory research, however, suggests high co-use between nicotine and prescription psychostimulants, and that these drugs interact to augment intake of either drug. The present review synthesizes epidemiological and experimental human and pre-clinical research assessing the behavioral and neuropharmacological interactions between nicotine and prescription psychostimulants that may contribute to high co-use between nicotine and prescription psychostimulants. Further, we discuss existing gaps in current knowledge. Nicotine has been less widely studied with alternative ADHD pharmacotherapies such as bupropion and atomoxetine, but we also discuss this research.